2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Sunday, November 13, 2016

9:00AM-11:00AM: Abstract Number: 116

Racial Differences in Self-Reported Pain and Disability: A Longitudinal Study of Knee Osteoarthritis

Healthcare Disparities in Rheumatology - Poster I

9:00AM-11:00AM: Abstract Number: 154

Radiographic Knee Osteoarthritis in Patients Complaining of Knee Pain: Ultrasound Features

Imaging of Rheumatic Diseases - Poster I: Ultrasound and Emerging Technologies

9:00AM-11:00AM: Abstract Number: 716

Radiographic Progression and Changes in Inflammation and Structural Damage on Serial MRI Examinations over 5 Years in Patients with Ankylosing Spondylitis Treated with TNF-Alpha Inhibitors

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster I: Axial and Peripheral Spondyloarthritis – Clinical Aspects, Imaging and Treatment

9:00AM-11:00AM: Abstract Number: 588

Radiographic Progression Is Less Significant in Anti-Carbamylated Antibody-Positive Patients with Rheumatoid Arthritis (RA) Who Were Clinically Active and Under the Treatment with Biological Dmards

Rheumatoid Arthritis – Human Etiology and Pathogenesis - Poster I

9:00AM-11:00AM: Abstract Number: 718

Radiographic Progression of Hip Arthritis in Patients with Ankylosing Spondylitis Treated with TNF Inhibitors

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster I: Axial and Peripheral Spondyloarthritis – Clinical Aspects, Imaging and Treatment

9:00AM-11:00AM: Abstract Number: 428

Random Forest Models Using Electronic Health Record Data Are Predictive of One-Year Outcomes in Lupus Nephritis Patients Taking Mycophenolate Mofetil Induction Therapy

Quality Measures and Quality of Care - Poster I

9:00AM-11:00AM: Abstract Number: 797

Randomized Clinical Trials of Systemic Lupus Erythematosus: Evaluating Differences in the Enrolled Populations

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster I: Clinical Trial Design and Current Therapies

9:00AM-11:00AM: Abstract Number: 118

Rates and Determinants of Persistent Patient-Physician Discordance in Global Assessment of Disease Activity in Latinos with Rheumatoid Arthritis in the United States

Healthcare Disparities in Rheumatology - Poster I

9:00AM-11:00AM: Abstract Number: 599

Real World United States-Based Clinical Experience with Prior Biologic Use Among First Time Golimumab Intravenous and Infliximab Treated Rheumatoid Arthritis Patients

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster I

9:00AM-11:00AM: Abstract Number: 145

Reduction in Musculoskeletal Ultrasound (MSK-US) Payments in 2014: Effects & Consequences

Imaging of Rheumatic Diseases - Poster I: Ultrasound and Emerging Technologies

9:00AM-11:00AM: Abstract Number: 641

Reduction of Concomitant Oral Methotrexate or Corticosteroids in Combination Treatment with Adalimumab Does Not Affect Effectiveness in Patients with Rheumatoid Arthritis

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster I

9:00AM-11:00AM: Abstract Number: 105

Regional Primary Care Rheumatology Networks for Patients with Rheumatic and Musculoskeletal Diseases: Need for a National Approach

Health Services Research - ARHP Poster

9:00AM-11:00AM: Abstract Number: 664

Regulation of Interferon Signaling By a Calcium-Induced miRNA in Primary Human Salivary Gland Epithelial Cells

Sjögren's Syndrome - Poster I: Translational Science

9:00AM-11:00AM: Abstract Number: 291

Relation of Foot Pronation during Walking to Risk of Worsening Lateral Patellofemoral and Medial Tibiofemoral Cartilage Damage

Osteoarthritis – Clinical Aspects - Poster I

9:00AM-11:00AM: Abstract Number: 370

Relationship Between Alcohol Consumption and Symptom Severity in Chronic Pain Patients

Pain – Basic and Clinical Aspects - Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].